Preclinical and clinical study on type 3 metabotropic glutamate receptors in Parkinson’s disease

Preclinical and clinical study on type 3 metabotropic glutamate receptors in Parkinson’s disease

Abstract Metabotropic glutamate (mGlu) receptors are candidate drug targets for therapeutic intervention in Parkinson’s disease (PD). Here we focused on mGlu3, a receptor subtype involved in synaptic regulation and neuroinflammation. mGlu3−/− mice showed an enhanced nigro-striatal damage and microgl...

Full description

Saved in:
Bibliographic Details
Main Authors: Luisa Di Menna, Marika Alborghetti, Maria Ilenia De Bartolo, Marina Borro, Giovanna Gentile, Manuela Zinni, Matteo Bologna, Carolina Cutrona, Giovanna D’Errico, Tiziana Imbriglio, Domenico Bucci, Sara Merlo, Roxana Paula Ginerete, Rosamaria Orlando, Federica Carrillo, Giorgio Fortunato, Milena Cannella, Maria Angela Sortino, Julien Pansiot, Olivier Baud, Ferdinando Nicoletti, Valeria Bruno, Maurizio Simmaco, Francesco Ernesto Pontieri, Edoardo Bianchini, Domiziana Rinaldi, Amalia de Curtis, Giovanni De Gaetano, Licia Iacoviello, Teresa Esposito, Alfredo Berardelli, Giuseppe Battaglia
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:npj Parkinson's Disease
Online Access:https://doi.org/10.1038/s41531-024-00860-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41531-024-00860-6

Similar Items